Sunshine Biopharma Financials - Benzinga

Sunshine Biopharma Inc

SBFMNASDAQ

Trade with Public

Trade with Public

$0.8426

0.04255.31%

近くで: Sep 25, 5:00 PM EST

$0.8262

-0.0164-1.95%

時間外: 7:21 PM EST

概要ニュース業績予想目標株価財務センチメント株主構成比較株式レポート

Sunshine Biopharma Financials

Sunshine Biopharma (SBFM) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Sunshine Biopharma Q1 EPS $(0.44) Up From $(2.00) YoY, Sales $8.90M Up From $7.54M YoY

Benzinga Newsdesk

Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug

Sunshine Biopharma's K1.1 mRNA-LNP shows promise for HCC treatment in mice, while its 2024 revenue surged 45% to $34.9 million.

Vandana Singh

PRO
Sunshine Biopharma 2024 Revenue $34.9M Up From $24.1M YoY

Benzinga Newsdesk

PRO
Sunshine Biopharma Q3 2024 GAAP EPS $(0.94), Sales $8.435M

Benzinga Newsdesk

PRO
Sunshine Biopharma Q2 EPS $(9.94) Misses $(0.37) Estimate, Sales $9.30M Beat $9.00M Estimate

Sunshine Biopharma (NASDAQ:SBFM) reported quarterly losses of $(9.94) per share which missed the analyst consensus estimate of $(0.37) by 2586.49 percent. This is a 86.03 percent increase over losses of $(71.17) per

Benzinga Newsdesk

PRO
Sunshine Biopharma Q1 EPS $(2.00) Misses $(1.04) Estimate, Sales $7.54M Beat $7.00M Estimate

Sunshine Biopharma (NASDAQ:SBFM) reported quarterly losses of $(2.00) per share which missed the analyst consensus estimate of $(1.04) by 92.31 percent. This is a 75 percent increase over losses of $(8.00) per share from

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved